Identification of key residues involved in the activation and signaling properties of dopamine D3 receptor

被引:6
|
作者
Kota, Kokila [1 ]
Kuzhikandathil, Eldo V. [1 ]
Afrasiabi, Milad [1 ]
Lacy, Brett [2 ]
Kontoyianni, Maria [2 ]
Crider, A. Michael [2 ]
Song, Daniel [3 ]
机构
[1] Rutgers New Jersey Med Sch, Dept Pharmacol Physiol & Neurosci, Newark, NJ 07103 USA
[2] So Illinois Univ, Dept Pharmaceut Sci, Edwardsville, IL 62026 USA
[3] Johnson & Johnson, China Cent Pl, Beijing 10025, Peoples R China
关键词
Dopamine receptor; PBZI; Desensitization; Tolerance; Adenylate cyclase; MAPK; Potassium channel; Locomotor behavior; TOLERANCE PROPERTY; LOCOMOTOR-ACTIVITY; LIGAND-BINDING; DOCKING; AGONISTS; CELLS; MICE; SENSITIVITY; PRAMIPEXOLE; CHANNELS;
D O I
10.1016/j.phrs.2015.05.016
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The dopamine D3 receptor exhibits agonist-dependent tolerance and slow response termination (SRT) signaling properties that distinguish it from the closely-related D2 receptors. While amino acid residues important for D3 receptor ligand binding have been identified, the residues involved in activation of D3 receptor signaling and induction of signaling properties have not been determined. In this paper, we used cis and trans isomers of a novel D3 receptor agonist, 8-OH-PBZI, and site-directed mutagenesis to identify key residues involved in D3 receptor signaling function. Our results show that trans-8-OH-PBZI, but not cis-8-OH-PBZI, elicit the D3 receptor tolerance and SRT properties. We show that while both agonists require a subset of residues in the orthosteric binding site of D3 receptors for activation of the receptor, the ability of the two isomers to differentially induce tolerance and SRT is mediated by interactions with specific residues in the sixth transmembrane helix and third extracellular loop of the D3 receptor. We also show that unlike cis-8-OH-PBZI, which is a partial agonist at the dopamine D2S receptor and full agonist at dopamine D2L receptor, trans-8-OH-PBZI is a full agonist at both D2S and D2L receptors. The different effect of the two isomers on D3 receptor signaling properties and D2S receptor activation correlated with differential effects of the isomers on agonist-induced mouse locomotor activity. The two isomers of 8-OH-PBZI represent novel pharmacological tools for in silica D3 and D2 receptor homology modeling and for determining the role of D3 receptor tolerance and SRT properties in signaling and behavior. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:174 / 184
页数:11
相关论文
共 50 条
  • [21] Identification of a novel dopaminergic agonist that selectively activates the D3 dopamine receptor
    Moritz, Amy E.
    Free, R. Benjamin
    Conroy, Jennie
    Doyle, Trevor
    Southall, Noel
    Ferrer, Marc
    Donthamsetti, Prashant
    Javitch, Jonathan A.
    Sibley, David R.
    FASEB JOURNAL, 2013, 27
  • [22] Enhancement of dopamine-induced signaling responses in the forebrain of mice lacking dopamine D3 receptor
    Mizuo, K
    Narita, M
    Miyatake, M
    Suzuki, T
    NEUROSCIENCE LETTERS, 2004, 358 (01) : 13 - 16
  • [23] The dopamine D3 receptor as a therapeutic target
    Schwartz, JC
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S166 - S167
  • [24] The D3 dopamine receptor and substance dependence
    Richtand, NM
    Goldsmith, RJ
    Nolan, JE
    Berger, SP
    JOURNAL OF ADDICTIVE DISEASES, 2001, 20 (03) : 19 - 32
  • [25] The dopamine D3 receptor and drug addiction
    Pierre Sokoloff
    Bernard Le Foll
    Sylvie Perachon
    Regis Bordet
    Sophie Ridray
    Jean-Charles Schwartz
    Neurotoxicity Research, 2001, 3 : 433 - 441
  • [26] The dopamine D3 receptor and drug addiction
    Sokoloff, Pierre
    Le Foll, Bernard
    Perachon, Sylvie
    Bordet, Regis
    Ridray, Sophie
    Schwartz, Jean-Charles
    NEUROTOXICITY RESEARCH, 2001, 3 (05) : 433 - 441
  • [27] The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors
    Wicke, K
    Garcia-Ladona, J
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 424 (02) : 85 - 90
  • [28] ASSOCIATION BETWEEN DOPAMINE D3 RECEPTOR GENOTYPE AND RESPONSE TO A DOPAMINE D3 RECEPTOR ANTAGONIST IN SCHIZOPHRENIC SUBJECTS.
    Bhathena, A.
    Wang, Y.
    Kraft, J. B.
    Idler, K. B.
    Abel, S. J.
    Holley-Shanks, R. R.
    Robieson, W. Z.
    Spear, B. B.
    Redden, L.
    Katz, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S76 - S76
  • [29] Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor
    Wood, MD
    Boyfield, I
    Nash, DJ
    Jewitt, FR
    Avenell, KY
    Riley, GJ
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 407 (1-2) : 47 - 51
  • [30] Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists
    Xu, Wei
    Wang, Xiaozhao
    Tocker, Aaron M.
    Huang, Peng
    Reith, Maarten E. A.
    Liu-Chen, Lee-Yuan
    Smith, Amos B., III
    Kortagere, Sandhya
    ACS CHEMICAL NEUROSCIENCE, 2017, 8 (03): : 486 - 500